Beaten Down Biotech Stocks that Could Rally in 2022


[ad]

Biotech is still one of the most exciting sectors to invest in.

By 2025, the global biotech market could be worth up to $720 billion, according to Global Market Insights.

Two, the sector is still one of the safest, most recession-proof investments around. Three, an aging population is demanding more treatments in an effort to live longer lives. At the moment, there are 65 million people over the age of 70 in the United States. As this number continues to grow, we’ll see a need for more medication and treatment options.

There’s also incredible new innovation in genetics and technology, creating new life-saving and life enhancing opportunities. And three, big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls created by patent expirations.

Moderna (MRNA)


[ad]

With the coronavirus still making the rounds, and US FDA approval for its booster shots, Moderna could race higher. At the moment, it’s just beginning to pivot higher from strong support at $225. We’d like to see an eventual bearish gap refill around $332, near-term, and potential test of $450 again, longer-term.

In addition, Piper Jaffray analyst Edward Tenthoff now has a $348 price target on MRNA after the US FDA news. “Moderna’s booster can be given following any primary approved Covid vaccination, which is important as Moderna could gain share from Pfizer (PFE) in the booster market, Tenthoff tells investors in a research note,” as noted by TheFly.com.

Fate Therapeutics (FATE)

Fate Therapeutics just reported that, “The interim Phase 1 data from our FT516 and FT596 programs in relapsed / refractory lymphoma demonstrate that our off-the-shelf, iPSC-derived NK cell product candidates have the potential to deliver substantial therapeutic benefit for patients along with a differentiated safety profile that supports outpatient treatment. We look forward to sharing additional clinical data from both of these programs at the American Society of Hematology Annual Meeting in December,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

“We also continue to be pleased with the clinical advancement of our multiplexed-engineered, iPSC-derived NK cell pipeline, where we have now successfully treated the first patients with FT516 in disease-specific expansion cohorts for lymphoma and with FT538 in combination with daratumumab for multiple myeloma. Additionally, we have successfully completed GMP manufacture and release of FT576, our multi-antigen targeted CAR BCMA product candidate for multiple myeloma, and have initiated enrollment in our Phase 1 study.”

Ultragenyx Pharmaceutical (RARE)

“In the third quarter we executed on key commercial and clinical milestones, including the resumption of the GTX-102 study for the treatment of Angelman syndrome and the initiation of our seamless Phase 1/2/3 study of UX701 for the treatment of Wilson disease. Looking ahead, we are preparing to initiate four additional studies across multiple modalities, including two Phase 3 gene therapies, a Phase 2/3 anti-sclerostin monoclonal antibody, and a Phase 1/2 leveraging our first mRNA program,” said Emil D. Kakkis, M.D., Ph.D., CEO and President of Ultragenyx. “The breadth of our clinical programs with the strength of our balance sheet put us in position to deliver disease-modifying therapies across a spectrum of rare diseases.”

Previous

Next